CaverSTIM
Phase 1- Indications
- Erectile dysfunction
Company intelligence / Profile preview
Comphya
Ecublens, Vaud, Switzerlandcomphya.com ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Phase 1
01
Overview
CaverSTIM, the company’s lead product, has shown proof-of-concept in acute clinical trials and has entered pilot clinical studies. Early results are promising for restoring erectile function via selective cavernous nerve stimulation in patients unresponsive to oral drugs. The company recently secured Series A funding to expand these trials internationally.
- Therapeutic areas
- Men's Health
- Modalities
- Device (implantable neurostimulator)Neurostimulation systemMedical device
- Industry
- Implantable Medical Devices
02
Drug pipeline
1 asset03
Partnerships
Collaborations with key opinion leaders and academic advisors from major institutions such as Prof. Arthur Burnett, Prof. Anthony Costello, Prof. Sidney Glina, Dr. Phil Dundee; no major pharma/biotech partnerships disclosed yet.
Beyond the preview
Go deeper on Comphya.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Comphya.